Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)

Key Points

• Maravai LifeSciences experienced a significant increase in options trading, with 1,002 put options acquired, marking a 1,791% increase over its typical volume.
• Royal Bank of Canada lowered its price target for Maravai shares from $7.00 to $5.00, while maintaining an "outperform" rating; the consensus rating remains "Hold" at an average target price of $5.22.
• Institutional investors currently own 50.25% of Maravai LifeSciences stock, with several hedge funds recently acquiring new positions in the company.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders purchased 1,002 put options on the stock. This is an increase of approximately 1,791% compared to the average volume of 53 put options.

Analyst Ratings Changes

Separately, Royal Bank Of Canada dropped their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating for the company in a research report on Tuesday, August 12th. Three equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $5.22.

Maravai LifeSciences Stock Down 6.2%

Shares of MRVI traded down $0.18 during midday trading on Friday, hitting $2.70. The company had a trading volume of 3,640,754 shares, compared to its average volume of 1,108,864. The company's 50 day moving average price is $2.50 and its 200 day moving average price is $2.32. The stock has a market cap of $689.47 million, a price-to-earnings ratio of -1.99 and a beta of 0.29. Maravai LifeSciences has a 52 week low of $1.66 and a 52 week high of $8.99. The company has a quick ratio of 4.49, a current ratio of 5.16 and a debt-to-equity ratio of 0.68.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Callan Family Office LLC acquired a new position in shares of Maravai LifeSciences in the 2nd quarter valued at about $25,000. Ethic Inc. acquired a new position in shares of Maravai LifeSciences in the 2nd quarter valued at about $26,000. McAdam LLC acquired a new position in shares of Maravai LifeSciences in the 1st quarter valued at about $31,000. Sherbrooke Park Advisers LLC acquired a new position in shares of Maravai LifeSciences in the 4th quarter valued at about $78,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Maravai LifeSciences in the 1st quarter valued at about $32,000. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.